UncategorizedEmeritusDX and KDx Diagnostics Inc. Announce a Partnership to Offer the URO17 NON-INVASIVE Urine Test for Bladder CancerNovember 10, 20220
UncategorizedKDx Diagnostics And Lister Hospital Announce The Launch Of A Non-Invasive URO17® Urine Test For Bladder Cancer In The United KingdomDecember 7, 20210
UncategorizedKDx Diagnostics, Cardiff University, Cardiff and Vale University Health Board and Cellpath announceJune 3, 20210
Uncategorized07/03/20 KDx Diagnostics Announces CE Marking for Innovative Non-invasive URO17™ Bladder Cancer TestJuly 26, 20200
Uncategorized01/08/20 KDx Diagnostics announces FDA Breakthrough Device designation for URO17™, Innovative urineJanuary 8, 20200
UncategorizedDemonstration of Keratin 17 Biomarker for Urothelial Carcinoma DetectionNovember 3, 20190